Molecular Diagnostics Market was valued at US$ 6,242.6 million in 2018 and is anticipated to reach US$ 9,546.2 million by 2025

Published Apr 26 


David Thomus
By David Thomus

55 Articles


Global Molecular Diagnostics Market was valued at US$ 6,242.6 million in 2018 and is anticipated to reach US$ 9,546.2 million by 2025 displaying a reasonable CAGR of 6.3% over the forecast period (2019-2025). Molecular diagnostics is referred to as the detection of genomic variants that aims to facilitate detection, diagnosis, sub-classification, prognosis, and monitoring response to therapy. It is a transformative and dynamic segment of diagnostics that leads to insights in research and treatment of various disease states which are revolutionizing healthcare. The growth in the diagnostics sector and personalized therapy is being driven by opportunities in molecular diagnostics. MDx took a prominent place in the clinical diagnostic laboratory and has shown various advantages for routine detection, fingerprinting, and epidemiologic analysis of infectious microorganisms.

Download Free Sample of this Report-

The field of molecular diagnostics has seen much growth in the clinical setting, providing rapid and sensitive approaches for the detection and monitoring of a wide range of human ailments. There is very real potential for molecular diagnostics to revolutionize patient care, offering tools that go further than the simple characterization of disease, reaching into the domain of characterizing the patient. The rapidly advancing technologies supporting molecular diagnostics are poised to change - possibly even revolutionize - medical diagnostics and treatment for the better. These improvements are creating diagnostic assays a more useful tool in a broader range of clinical paradigms. Currently, about 75% of infections remain undiagnosed, often just treated with broad-spectrum antibiotics.

Global Molecular Diagnostics market by product type is bifurcated in reagents and instruments services. The reagents segment is anticipated to dominate the global molecular diagnostics market holding 69% of the total market during the forecast period due to the increasing utilization of therapies as a treatment to several conditions. The reagent segment represents the level of quality required when developing tests for the clinical market.

Polymerase Chain Reaction (PCR), Transcription-Mediated Amplification (TMA), In Situ Hybridization, DNA Sequencing & Next-Generation Sequencing (NGS), Chips and Microarrays and others are several techniques being utilized in Molecular Diagnostics. The PCR segment occupied the largest share in the molecular diagnostics market. In recent decades, the advent of the quantitative real-time PCR (qPCR) has shown to gain popularity for the detection of pathogens in clinical microbiology. The current advancement in PCR has led to the development of isothermal amplification methods, including Loop-Mediated Isothermal Amplification (LAMP) and Polymerase Spiral Reaction (PSR).

The molecular diagnostics market has been segmented in various application fields such as Microbiology, Virology, Hospital Acquired Infections (HAI), Genetic Testing, Oncology, Pharmacogenetics, Human Leukocytes Antigen (HLA), Blood Screening and others. The virology segment dominated the market and is anticipated to dominate the same during the forecast period. However, the Oncology application segment is expected to witness the highest CAGR growth of 8.27% during the forecast period 2019-2025. There are multiple applications of molecular tests in clinical oncology. Mutation analysis is now routinely utilized for the diagnosis of hereditary cancer syndromes. Personalized selection of cancer drugs based on the presence of actionable mutations has become an integral part of cancer therapy. Molecular tests underlie the administration of EGFR, BRAF, ALK, ROS1, PARP inhibitors as well as the use of some other cytotoxic and targeted drugs.

Request To Download Sample of this Strategic Report-

The molecular diagnostics market is bifurcated in hospitals, clinics & labs, and others by the end-user segment. The hospital segment is anticipated to dominate the molecular diagnostics market during the forecast period. Today molecular diagnostics is a game-changer for clinical laboratories of all sizes, offering more powerful tools for earlier and more accurate detection of disease and giving laboratories a key role in the emerging field of personalized medicine. The simplification of molecular assays and instruments will foster wider implementation by community hospital laboratories. With these new, more efficient systems, hospital laboratories are also seeing increased revenue opportunities.

For a deep-dive analysis of the industry, detailed regional/country-level analysis is conducted for markets including North America (US, Canada, Rest of US), Europe (Germany, France, Spain, Italy, UK, Rest of Europe), Asia-Pacific (China, Japan, India, Australia and Rest of Asia-Pacific) and Rest of World (Brazil and Other Rest of World). In 2018, North America generated revenue of US$ 2,964.9 million, however, Asia-Pacific is expected to witness the highest CAGR of 6.74% during the forecast period. The dominance of North America is majorly driven by the presence of a well-established diagnostic infrastructure, technological advancements, patient awareness, and the presence of advanced products in the field of molecular diagnostics.

Abbott Laboratories, Becton Dickinson and Company, Biomerieux SA, Danaher Corporation, Hologic, Inc., Qiagen, Roche, Siemens Healthineers AG, Sysmex Corporation and Thermo Fisher Scientific are some of the prominent players operating in the Global Molecular Diagnostics market industry. Several M&A’s along with partnerships have been undertaken by these players to facilitate costumers with hi-tech and innovative products.

Global Molecular Diagnostics Market Segmentation

Market Insights, by Product

  • Reagents
  • Instruments Services

Market Insights, by Technique

  • Polymerase chain reaction (PCR)
  • Transcription-Mediated Amplification (TMA)
  • In Situ Hybridization & FISH
  • DNA Sequencing & Next-Generation Sequencing (NGS)
  • Chips and Microarrays
  • Others

Market Insights, by Application

  • Microbiology
  • Virology
  • Hospital Acquired Infections (HAI)
  • Genetic Testing
  • Oncology
  • Pharmacogenetics
  • Human Leukocyte Antigen (HLA Testing)
  • Blood Screening
  • Others

Market Insights, by End-User

Market Insights, by Region

  • North America
  • United States
  • Canada
  • Rest of NA
  • Europe
  • Germany
  • United Kingdom
  • France
  • Italy
  • Spain
  • Rest of Europe
  • Asia-Pacific
  • China
  • Japan
  • Australia
  • India
  • Rest of APAC
  • Rest of World
  • Brazil
  • Other Rest of World

Top Company Profiles

  • Abbott Laboratories
  • Becton, Dickinson, and Company
  • Biomérieux SA
  • Hologic
  • Danaher Corporation
  • Qiagen
  • Roche Holding AG
  • Siemens Healthineers AG
  • Thermo Fisher Scientific
  • Sysmex Corporation


  • Table Of Content:

  • 1 MARKET INTRODUCTION
  • 2 RESEARCH METHODOLOGY
  • 3 COMPREHENSIVE ASSESSMENT OF THE VALUE OF DIAGNOSTIC TESTS
  • 4 REFRAMING THE DIAGNOSTICS INDUSTRY
  • 5 EXECUTIVE SUMMARY
  • 6 INDUSTRY PERFORMANCE
  • 7 RISK MITIGATION
  • 5 MARKET OVERVIEW
  • 6 REGULATIONS AND REIMBURSEMENT POLICY
  • 7 KEY MARKET INDICATORS
  • 8 MARKET INSIGHT BY PRODUCT
  • 9 MARKET INSIGHT BY TECHNIQUE
  • 10 MARKET INSIGHT BY APPLICATION
  • 11 MARKET INSIGHT BY END USER
  • 12 MARKET INSIGHT BY REGION
  • 13 COMPETITIVE SCENARIO
  • 14 TOP COMPANY PROFILES
  • 18 TOP COMPANY PROFILES

News

Advertisement